Brochure | Cardiovascular Diseases

Cardiology degree of Faridabad doctor posing as cardiologist found fake, police probe reveals

2025-06-13 - 2025-06

Faridabad, The cardiology degree of the MBBS-qualified doctor who allegedly posed as a cardiologist and performed more than 50 heart surgeries in over eight months at a government hospital here was found to be fake, police investigation revealed.

Cardiology degree of Faridabad doctor posing as cardiologist found fake, police probe reveals

2025-06-11 - 2025-06

Cardiology degree of Faridabad doctor posing as cardiologist found fake, police probe reveals Faridabad, The cardiology degree of the MBBS-qualified doctor who allegedly posed as a cardiologist and performed more than 50 heart surgeries in over eight months at a government hospital here was found to be fake, police investigation revealed.

Dr. Ralph Nader Joins New UHealth Doral Cardiology Program

2025-06-11 - 2025-06

UHealth’s cardiology program has expanded to UHealth Doral. The new practice will feature prominent cardiologist Ralph Nader, M.D., who has practiced in Miami for 35 years and will be one of the key practitioners in Doral. Along with general cardiology, the clinic will focus on subspecialities such as hypertension, electrophysiology, interventional cardiology and treatments for heart failure. It will offer a multitude of diagnostic imaging techniques, from electrocardiograms and stress echocardiography to cardiac MRI, cardiac MRI and nuclear cardiology imaging like SPECT and PET.

Two UK Cardiology Trials Struggle to Recruit Patients

2025-06-10 - 2025-06

Two ongoing cardiology trials in the UK are facing substantial recruitment challenges, researchers reported at the British Cardiovascular Society (BCS) Annual Conference 2025. The BRITISH study has enrolled fewer than one third of its targeted 2504 patients over 2 years. Meanwhile, CRAAFT-HF has recruited just 22 of its 1200-patient goal since launching in December 2024.

Delays in Aortic Valve Replacement Procedures in the UK

2025-06-07 - 2025-06

Research indicates that over 400 patients with aortic stenosis die annually while awaiting transcatheter aortic valve implantation (TAVI) on NHS waiting lists. The average wait time is 142 days, highlighting the need for increased procedural capacity and equitable access.

Ziltivekimab: Investigational Anti-Inflammatory Therapy

2025-06-06 - 2025-06

Ziltivekimab, a monoclonal antibody targeting interleukin-6, is under investigation for treating inflammatory conditions like cardiovascular disease and chronic kidney disease. Clinical trials have shown its potential in reducing inflammatory biomarkers and improving anemia-related parameters.

LILACS Trial: T Cell Regulation in Acute Coronary Syndrome

2025-06-05 - 2025-06

The LILACS trial has demonstrated that low-dose interleukin-2 therapy can expand regulatory T cells, reducing inflammation in patients with acute coronary syndrome. This finding offers new insights into immunomodulatory approaches in cardiology.

EECP Treatment Centers in India

2025-06-03 - 2025-06

Heal your Heart is a reputed EECP treatment center in India. It is an organization that is the pioneer in bringing EECP treatment to India. Heal your Heart EECP treatment centers are units of Vaso-Meditech Private Limited, Chennai, India. The organization is the brainchild of Dr.S.Ramasamy, a qualified physician with an exceptional reputation in Non-Invasive cardiac care and a renowned International expert in EECP Treatment.Vaso-Meditech Enhanced External Counterpulsation (EECP) helps to form new blood vessels naturally, and it's a proven alternative treatment for bypass surgery and Angioplasty. It is a reputed organization of proficient doctors and professionals delivering pioneering heart care solutions through EECP treatment is an alternative treatment when the patient prefers Heart Blockage Removal Without Surgery.

Faster CPR Saves Lives: Delay Beyond 4 Minutes Reduces Survival in Out-of-Hospital Cardiac Arrest, Study Finds

2025-06-02 - 2025-06

The study strongly suggests that every second counts in the critical moments following a cardiac arrest. Early initiation of CPR, particularly with dispatcher guidance, can make a substantial difference in saving lives and preserving brain function.

About 56% of men who suffered heart attack were current smokers: Study

2025-05-31 - 2025-05

Prof Rajesh Vijayvergiya, Department of Cardiology at PGI, emphasises the role of cardiologists in promoting tobacco cessation to prevent cardiovascular diseases. He advocates for integrating cessation support into routine cardiac care and raising awareness about tobacco’s heart health risks.

Sports Cardiology: Emphasis on Personalized Care

2025-05-28 - 2025-05

The 2025 American College of Cardiology (ACC) Scientific Session highlighted a shift towards individualized care in sports cardiology. New guidelines from the American Heart Association (AHA) and ACC advocate for shared decision-making, especially for athletes with heart conditions. Notably, recent data suggest that athletes with certain cardiomyopathies may not face higher arrhythmic risks than non-athletes, allowing for more personalized return-to-play decisions.

Introduction to Karoo Health and why Value-Based Cardiology Care is the Next Frontier

2025-05-27 - 2025-05

The next frontier of value-based care is, of course, value-based specialty care (VBSC). We know the stats around the opportunity and level of spend present in downstream specialty care segments. In my ‘2024 state of value-based care enablement’ piece in 2024, I talked about several companies in the value-based specialty care game across kidney care, MSK, oncology, and…cardiology.

Tennessee cardiologist opens up about the silent grief doctors carry after every patient loss: 'I cry'

2025-05-26 - 2025-05

Doctors are often seen as composed professionals, trained to remain calm and collected even in life-and-death situations. But what happens when a doctor loses a patient despite doing everything possible to save them. A deeply emotional Instagram post by a Tennessee-based cardiologist has gone viral, lifting the veil on a rarely discussed topic—how doctors cope when a patient dies.

IoT-Driven Cardiac Monitoring:

2025-05-21 - 2025-05

Researchers have developed a novel IoT-based solution for remote, real-time tracking of critical cardiac metrics, including heart rate and ECG. This system aims to provide accessible and continuous healthcare, particularly benefiting aging populations.

Dual mechanotherapy for the treatment of cardiac fibrosis

2025-05-20 - 2025-05

Inhibition of mechanotransduction selectively in cardiac fibroblasts, especially when combined with inhibition of transforming growth factor- (TGF) signalling, triggers a reversal of fibroblast activation and suppresses fibrosis in diseased hearts, according to findings published in Nature.

Regular cardiologist visits may significantly cut death risk for heart failure patients:

2025-05-17 - 2025-05

A new study has revealed that heart failure patients who consult a cardiologist at least once a year have a significantly lower risk of death, yet only about 60 per cent of such patients actually make that visit.

IoT-Driven Cardiac Monitoring:

2025-05-17 - 2025-05

Combination Therapy for Cholesterol Management:

2025-05-16 - 2025-05

A study in Mayo Clinic Proceedings suggests that combining statins with ezetimibe significantly reduces the risk of early death, major cardiovascular events, and stroke more effectively than statins alone.

Lepodisiran for 'Stealthy' Cholesterol:

2025-05-15 - 2025-05

Eli Lilly's experimental drug, lepodisiran, shows promise in treating lipoprotein(a) or Lp(a), a genetic form of cholesterol affecting 1 in 5 people globally. Clinical trials indicate up to a 95% reduction in Lp(a) levels, with minimal side effects.

Ketogenic Diet and Heart Health:

2025-05-14 - 2025-05

A recent meta-analysis published in JACC Advances has sparked debate by suggesting that a ketogenic diet may contribute to plaque progression in arteries, challenging previous notions of its cardiovascular benefits.

Advancements in Defibrillation:

2025-05-13 - 2025-05

Medtronic has received FDA approval for its smallest-ever defibrillation lead, promising less invasive procedures and improved patient comfort.

AI-Powered Heart Scans:

2025-05-12 - 2025-05

Artificial intelligence is enhancing cardiovascular diagnostics. Notably, AI-ECG tools are now detecting heart risks in women planning pregnancy, aiding in early intervention strategies.

Lerodalcibep: Lowering LDL Cholesterol

2025-05-09 - 2025-05

Lerodalcibep, a PCSK9 inhibitor developed by LIB Therapeutics, is currently under FDA review for its potential to reduce LDL cholesterol in patients with atherosclerotic cardiovascular disease and familial hypercholesterolemia. If approved, it could provide an additional option for managing high cholesterol levels.

Lerodalcibep: Lowering LDL Cholesterol

2025-05-08 - 2025-05

Vutrisiran (AMVUTTRA): Addressing Hereditary Transthyretin Amyloidosis

2025-05-07 - 2025-05

In March 2025, the FDA approved vutrisiran (AMVUTTRA) for treating cardiomyopathy associated with hereditary transthyretin amyloidosis (hATTR). This RNA interference therapy offers a new avenue for managing this rare and progressive condition.

Acoramidis (Attruby): Treating Transthyretin Amyloid Cardiomyopathy

2025-05-06 - 2025-05

Acoramidis, marketed as Attruby, received approval in the U.S. in November 2024 and in the EU in February 2025 for treating transthyretin amyloid cardiomyopathy (ATTR-CM). This oral medication stabilizes the transthyretin protein, preventing amyloid deposits in the heart and reducing cardiovascular-related hospitalizations and deaths.

VERVE-102: Gene Editing for Cholesterol Reduction

2025-05-03 - 2025-05

Verve Therapeutics has reported promising results from its Phase 1b clinical trial of VERVE-102, a CRISPR-based gene-editing therapy targeting the PCSK9 gene. A single infusion achieved an average 59% reduction in LDL cholesterol among high-dose recipients, with no significant side effects. Unlike existing treatments requiring repeated doses, this approach offers a potentially lifelong solution. Phase 2 trials are expected to commence in the latter half of 2025.

Acoramidis (Attruby): Treating Transthyretin Amyloid Cardiomyopathy

2025-05-02 - 2025-05

Menopause Timing and Heart Health

2025-04-30 - 2025-04

Research indicates that women who experience menopause after age 55 have better vascular health and lipid profiles, likely due to prolonged estrogen exposure. However, heart disease risk increases post-menopause for all women, underscoring the need for regular monitoring.

Ginger's Cardiovascular Benefits

2025-04-29 - 2025-04

A 2025 study emphasized ginger's role in cardiovascular health, noting its ability to lower blood pressure, improve circulation, and stabilize lipid profiles. Daily consumption of 500 mg to 2 g is recommended, preferably in raw form.

Brisk Walking Reduces Arrhythmia Risk

2025-04-28 - 2025-04

A study of over 400,000 individuals revealed that brisk walking (over 4 mph) can reduce the risk of atrial fibrillation by nearly 50%. Even average-paced walking showed a 27% reduction, highlighting the benefits of regular physical activity.

Breast Arterial Calcification as a Predictor

2025-04-25 - 2025-04

An AI model analyzing mammograms can quantify breast arterial calcification (BAC), which independently predicts cardiovascular risk, especially in women under 50. This approach offers a non-invasive method for early detection.

AI-Derived Vascular Age from Wearables

2025-04-24 - 2025-04

Researchers have developed a deep learning model that estimates vascular age using photoplethysmography (PPG) signals from wearable devices. A significant gap between vascular and chronological age correlates with higher risks of cardiovascular events.

Statin-Ezetimibe Combo Post-Heart Attack

2025-04-23 - 2025-04

A study involving 36,000 patients found that early use of statins combined with ezetimibe post-heart attack significantly reduces the risk of subsequent cardiac events. Despite its affordability and efficacy, this combination is underutilized.

VERVE-102: Gene Editing for Cholesterol Control

2025-04-22 - 2025-04

Verve Therapeutics' VERVE-102, an in vivo base-editing therapy targeting the PCSK9 gene, has received FDA clearance for Phase 2 trials. This one-time treatment aims to permanently lower LDL cholesterol levels.

Lepodisiran: Targeting 'Stealth' Cholesterol

2025-04-21 - 2025-04

A new drug, lepodisiran, has shown promise in reducing lipoprotein(a) [Lp(a)] levels—a genetic cholesterol variant linked to heart attacks and strokes. In Phase 2 trials, it lowered Lp(a) by up to 95% with minimal side effects. Lp(a) often goes undetected in standard screenings and is resistant to lifestyle changes or statins.

Brisk Walking Benefits:

2025-04-19 - 2025-04

A University of Glasgow study involving over 421,000 participants found that brisk walking (over 4 mph) is associated with a nearly 50% lower risk of developing atrial fibrillation and a 39% reduced risk of other heart arrhythmias compared to slower walking speeds.

Bristol Myers' Mavacamten Trial

2025-04-17 - 2025-04

Bristol Myers Squibb's drug mavacamten did not meet primary goals in a late-stage trial for treating non-obstructive hypertrophic cardiomyopathy, though no new safety concerns emerged.

Statins + Ezetimibe Post-Heart Attack:

2025-04-16 - 2025-04

A study by Imperial College London and Lund University found that combining statins with ezetimibe shortly after a heart attack significantly reduces the risk of subsequent heart attacks, strokes, or death. This combination therapy, when initiated within 12 weeks post-heart attack, showed better outcomes compared to statin monotherapy.

HPV Infection Linked to Increased Heart Disease Risk

2025-04-15 - 2025-04

Recent research indicates that individuals infected with human papillomavirus (HPV) have a 40% higher likelihood of developing cardiovascular disease and twice the risk of coronary artery disease compared to HPV-negative individuals. The association remains significant even after accounting for other risk factors, suggesting that HPV vaccination could also contribute to reducing cardiovascular risks.

Simple Blood Test Enhances Heart Attack Prevention

2025-04-14 - 2025-04

Researchers have identified that measuring troponin levels—a protein released during heart muscle damage—can significantly improve the prediction of heart attacks and strokes. Incorporating troponin measurements into existing risk models enhances the accuracy of assessing a patient's 10-year cardiovascular risk, potentially leading to earlier interventions and prevention of numerous cardiovascular events annually.

Breakthrough in Heart Attack Prevention

2025-04-11 - 2025-04

A simple £5 blood test measuring troponin levels, traditionally used to diagnose heart attacks, has shown promise in predicting future cardiovascular events. By integrating troponin measurements into existing risk assessment models, doctors can more accurately predict a patient’s 10-year risk of cardiovascular events, especially in those currently deemed at intermediate risk. This approach could lead to timely preventive interventions and potentially prevent thousands of heart attacks and strokes annually.

Exercise Patterns and Heart Health

2025-04-10 - 2025-04

Research published in the Journal of the American Heart Association reveals that individuals can attain significant health benefits without exercising every day. The study found that both "Weekend Warriors" (those exercising primarily on weekends) and those active regularly throughout the week had significantly lower mortality risks from all causes, including cardiovascular disease and cancer, compared to inactive individuals—provided they achieved the recommended 150 minutes of weekly moderate physical activity.

Prevalence of Peripheral Artery Disease

2025-04-09 - 2025-04

A study by Intermountain Health indicates that peripheral artery disease (PAD) affects over 10 million Americans over age 40 and has a 50% mortality rate. PAD occurs when plaques narrow or block arteries supplying blood to the limbs, potentially leading to limb amputation. The study found that only about one-third of patients received appropriate treatment, highlighting the need for improved screening and targeted care systems.

Impact of Food Insecurity on Heart Disease

2025-04-08 - 2025-04

A study published in JAMA Cardiology found that young adults experiencing food insecurity have a 41% greater risk of developing heart disease in midlife, even after accounting for demographic and socioeconomic factors. This highlights the long-term cardiovascular risks associated with inadequate access to nutritious food.

Prevalence of Peripheral Artery Disease

2025-04-07 - 2025-04

Gene Therapy Reversing Heart Failure

2025-04-03 - 2025-04

Researchers at the University of Utah have developed a gene therapy that reverses heart failure effects in large animal models. By increasing a specific protein's expression, the therapy enhances the heart's pumping ability and significantly improves survival rates, indicating a potential breakthrough in heart failure treatment.

Scientists unveil starfish-inspired wearable tech for heart monitoring

2025-04-02 - 2025-04

When we move, it's harder for existing wearable devices to accurately track our heart activity. But researchers found that a starfish's five-arm shape helps solve this problem. Inspired by how a starfish flips itself over -- shrinking one of its arms and using the others in a coordinated motion to right itself -- scientists have created a starfish-shaped wearable device that tracks heart health in real time.

Lepodisiran's Impact on Lipoprotein(a)

2025-04-02 - 2025-04

Eli Lilly's experimental drug, lepodisiran, has demonstrated a nearly 94% reduction in lipoprotein(a) [Lp(a)] levels after a single dose. Elevated Lp(a) is a genetic factor increasing the risk of heart attacks and strokes, affecting approximately 64 million Americans. These findings were presented at the American College of Cardiology meeting and published in The New England Journal of Medicine.

Human Papillomavirus (HPV) and Cardiovascular Risk

2025-04-01 - 2025-04

Recent research indicates a significant association between HPV infection and increased heart disease risk. Individuals testing positive for HPV were found to have a 40% higher likelihood of developing cardiovascular disease and double the risk of coronary artery disease compared to those without the infection. This underscores the importance of HPV vaccination and monitoring for cardiovascular health.

Experimental Drug Shows Promise in Reducing Genetic Heart Disease Risk

2025-03-31 - 2025-03

Eli Lilly's experimental drug, lepodisiran, has demonstrated a significant reduction in lipoprotein(a) (Lp(a)) levels—a genetic risk factor for heart disease—by an average of 93.9% compared to placebo in a mid-stage trial. The study involved 141 patients receiving a 400 mg dose of lepodisiran and 69 receiving a placebo over six months, with no serious drug-related complications reported. These findings were presented at the American College of Cardiology meeting in Chicago and published in the New England Journal of Medicine.

HPV Infection and Heart Disease Risk

2025-03-28 - 2025-03

Recent studies have identified a significant association between human papillomavirus (HPV) infection and an increased risk of cardiovascular diseases. Individuals testing positive for HPV were found to have a 40% higher likelihood of developing cardiovascular conditions and double the risk of coronary artery disease compared to those without the infection. Researchers suggest that chronic inflammation caused by HPV may contribute to this elevated risk, highlighting the potential cardiovascular benefits of HPV vaccination.

New Cardiology Board Denied but ‘Not Done With This Fight’

2025-03-27 - 2025-03

Leaders of a group convened to establish a new, independent board for cardiology are reviewing options after the American Board of Medical Specialties (ABMS) rejected their application to establish the American Board of Cardiovascular Medicine and invoked a 2-year wait time to reapply.

New Evidence Links Microplastics with Chronic Disease

2025-03-26 - 2025-03

Tiny fragments of plastic have become ubiquitous in our environment and our bodies. Higher exposure to these microplastics, which can be inadvertently consumed or inhaled, is associated with a heightened prevalence of chronic noncommunicable diseases, according to new research being presented at the American College of Cardiology's Annual Scientific Session.

Smartwatches in Cardiovascular Monitoring

2025-03-24 - 2025-03

Research from Northwestern University Feinberg School of Medicine indicates that smartwatches can monitor heart health by tracking heart rate per step. An elevated daily heart rate per step (DHRPS) is associated with higher risks of type 2 diabetes, heart failure, high blood pressure, and coronary atherosclerosis. This suggests that smartwatch data could encourage individuals to seek medical advice and undergo further cardiovascular screening.

Webinar on Cardiovascular Diseases and Therapeutics

Brochure Form

Cardiology degree of Faridabad doctor posing as cardiologist found fake, police probe reveals

Cardiology degree of Faridabad doctor posing as cardiologist found fake, police probe reveals

Dr. Ralph Nader Joins New UHealth Doral Cardiology Program

Two UK Cardiology Trials Struggle to Recruit Patients

Delays in Aortic Valve Replacement Procedures in the UK

Ziltivekimab: Investigational Anti-Inflammatory Therapy

LILACS Trial: T Cell Regulation in Acute Coronary Syndrome

EECP Treatment Centers in India

Faster CPR Saves Lives: Delay Beyond 4 Minutes Reduces Survival in Out-of-Hospital Cardiac Arrest, Study Finds

About 56% of men who suffered heart attack were current smokers: Study

Sports Cardiology: Emphasis on Personalized Care

Introduction to Karoo Health and why Value-Based Cardiology Care is the Next Frontier

Tennessee cardiologist opens up about the silent grief doctors carry after every patient loss: 'I cry'

IoT-Driven Cardiac Monitoring:

Dual mechanotherapy for the treatment of cardiac fibrosis

Regular cardiologist visits may significantly cut death risk for heart failure patients:

IoT-Driven Cardiac Monitoring:

Combination Therapy for Cholesterol Management:

Lepodisiran for 'Stealthy' Cholesterol:

Ketogenic Diet and Heart Health:

Advancements in Defibrillation:

AI-Powered Heart Scans:

Lerodalcibep: Lowering LDL Cholesterol

Lerodalcibep: Lowering LDL Cholesterol

Vutrisiran (AMVUTTRA): Addressing Hereditary Transthyretin Amyloidosis

Acoramidis (Attruby): Treating Transthyretin Amyloid Cardiomyopathy

VERVE-102: Gene Editing for Cholesterol Reduction

Acoramidis (Attruby): Treating Transthyretin Amyloid Cardiomyopathy

Menopause Timing and Heart Health

Ginger's Cardiovascular Benefits

Brisk Walking Reduces Arrhythmia Risk

Breast Arterial Calcification as a Predictor

AI-Derived Vascular Age from Wearables

Statin-Ezetimibe Combo Post-Heart Attack

VERVE-102: Gene Editing for Cholesterol Control

Lepodisiran: Targeting 'Stealth' Cholesterol

Brisk Walking Benefits:

Bristol Myers' Mavacamten Trial

Statins + Ezetimibe Post-Heart Attack:

HPV Infection Linked to Increased Heart Disease Risk

Simple Blood Test Enhances Heart Attack Prevention

Breakthrough in Heart Attack Prevention

Exercise Patterns and Heart Health

Prevalence of Peripheral Artery Disease

Impact of Food Insecurity on Heart Disease

Prevalence of Peripheral Artery Disease

Gene Therapy Reversing Heart Failure

Scientists unveil starfish-inspired wearable tech for heart monitoring

Lepodisiran's Impact on Lipoprotein(a)

Human Papillomavirus (HPV) and Cardiovascular Risk

Experimental Drug Shows Promise in Reducing Genetic Heart Disease Risk

HPV Infection and Heart Disease Risk

New Cardiology Board Denied but ‘Not Done With This Fight’

New Evidence Links Microplastics with Chronic Disease

Smartwatches in Cardiovascular Monitoring

cardiology@confmeets.net

support@confmeets.net

+44-7477-467410